Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.55 |
| ▸ | TSLP | Q969D9 | 16/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857314 | 0.97 | KEAP1 (0.55) | KEAP1TSLP | |
| SCHEMBL13857317 | 0.96 | KEAP1 (0.54) | KEAP1TSLP | |
| SCHEMBL13857315 | 0.96 | KEAP1 (0.50) | KEAP1TSLPCACNA1B | |
| SCHEMBL13857316 | 0.94 | KEAP1 (0.55) | KEAP1TSLP | |
| SCHEMBL13857318 | 0.92 | KEAP1 (0.51) | KEAP1TSLPCACNA1B | |
| SCHEMBL13857319 | 0.90 | KEAP1 (0.53) | KEAP1TSLPCACNA1B | |
| SCHEMBL22342189 | 0.75 | KEAP1 (0.60) | KEAP1TSLP | |
| SCHEMBL25455142 | 0.74 | KEAP1 (0.53) | KEAP1TSLPCACNA1B | |
| SCHEMBL19682189 | 0.73 | KLKB1 (0.45) | KEAP1TSLPCACNA1B | |
| SCHEMBL30695101 | 0.73 | ITGB3 (0.51) | KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | KEAP1 611/4885TSLP 1162/4885CACNA1B 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.